SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital in Ahmedabad, India. The program commenced with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra 3.0 system. This marks a significant step in bringing advanced robotic cardiac surgery to the region and underscores the growing adoption of SS Innovations' technology in diverse clinical settings.
The procedure's success at HCG Hospital, Mithakhali, is not just a local milestone but a strategic move for SS Innovations as it seeks to penetrate new markets and demonstrate the versatility of its platform. Cardiac surgery is a complex, high-stakes specialty where robotic assistance can enhance precision and potentially improve patient outcomes. By enabling such procedures, SS Innovations positions itself as a key player in the global robotic surgery market, which is increasingly competitive and innovation-driven.
SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. This rapid growth reflects strong demand for the system, which is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. Such geographic diversification reduces reliance on any single market and signals the company's ability to navigate regulatory and clinical landscapes worldwide. The installation growth also provides a recurring revenue stream through service and consumables, which is crucial for long-term financial sustainability.
Moreover, the company is pursuing U.S. FDA review and European Union CE marking for the SSi Mantra, aiming to enter additional international markets. These regulatory milestones, if achieved, could significantly broaden the addressable market and further accelerate adoption. The expansion into cardiac surgery at HCG Hospital is likely to serve as a reference site, potentially attracting other hospitals in India and beyond to adopt the technology. As the company noted in a LinkedIn post, https://ibn.fm/TTTdR, it remains committed to enabling hospitals and surgeons with advanced robotic tools.
The implications of this announcement extend beyond SS Innovations. For hospitals, adopting robotic cardiac surgery can differentiate their services and attract patients seeking minimally invasive options. For surgeons, it offers enhanced visualization and dexterity, potentially reducing complications and recovery times. For the broader healthcare ecosystem, it signals a shift toward robotics in specialties traditionally dominated by open surgery, which could lead to better clinical outcomes and cost efficiencies over time.
Investors and industry watchers should note that SS Innovations' growth trajectory is supported by tangible metrics: a 42% increase in installations in just over eight months and a presence in 12 countries. The company's focus on regulatory approvals in the U.S. and Europe could unlock substantial value, as these markets are early adopters of surgical robotics. However, challenges remain, including competition from established players and the need for robust clinical evidence to drive adoption. The full details of the release are available at Read More, and investors can find ongoing updates in the company's newsroom at https://ibn.fm/SSII. As SS Innovations continues to execute its expansion strategy, its progress will be closely monitored for signs of sustained momentum in the robotic surgery sector. For terms of use and disclaimers, see https://IBN.ai/Disclaimer.
